Dactinomycin

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

EMLc ATC codes: L01DA01

Indication	Rhabdomyosarcoma primary site ICD11 code: 2B55.Z
INN	Dactinomycin
Medicine type	Chemical agent
List type	Complementary
Formulations	**Parenteral > General injections > IV:** 500 µg in vial powder for injection
EML status history	First added in 1984 (TRS 722) Changed in 2015 (TRS 994)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer
Wikipedia	Dactinomycin
DrugBank	Dactinomycin

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for dactinomycin on the complementary list of the EML and EMLc for use in treatment protocols for rhabdomyosarcoma was specifically endorsed. The relevant extracts from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for rhabdomyosarcoma is attached.